Biologic therapies in autoimmune diseases

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 6, Issue 1, 2006, Pages 105-108

  Penn, Henry ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Autoimmune diseases; Biologic therapies; Etanercept; Infliximab; Rheumatoid disease; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ANTIBODY; ANTINUCLEAR ANTIBODY; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 6; LYMPHOTOXIN; METHOTREXATE; RECEPTOR PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BEHCET DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NONHODGKIN LYMPHOMA; NONHUMAN; PEMPHIGUS VULGARIS; POLYCHONDRITIS; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

EID: 33644544389     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.6-1-105     Document Type: Review

References (6)

1. National Institute for Health and Clinical Excellence. Guidance on the use of etanercept and infliximab for rheumatoid arthritis. NICE Technology Appraisal Guidance no 36. London: NICE, 2002. Available from www.nice.org.uk
2. Klareskog L, van der Heijde D, de Jager JP, Gough A et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
3. Capell H, Stirling A, McMahon AD, Grigor C et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
4. Keat A, Barkham N, Bhalla A, Gaffney K et al. BSR guidelines for prescribing TNF blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 2005;44(7):939-47.
5. Smith CH, Anstey AV, Barker JNWN, Burden AD. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Derm 2005;153:486.
6. Kremer JM, Westhovens R, Leon M, Di Giorgio E et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.